The GOP-led House Judiciary Committee is requesting records from Pfizer’s CEO and an interview with a former company executive to investigate an allegation that clinical testing related to the ...

Pfizer's CEO said President Donald Trump's tariffs and uncertainty are holding the company back from making "tremendous investments" in the US. In a first-quarter earnings call on Tuesday, chief ...

The price of the lifesaving Covid-19 antiviral medication Paxlovid will more than double as the United States transitions out of the emergency phase of the pandemic, drugmaker Pfizer said Wednesday.

Pfizer PFE-0.88 % decrease; red down pointing triangle had a problem. Doctors weren’t prescribing its migraine drug Nurtec because they assumed insurance coverage would be too much of a hassle.

The report said GSK’s former head of vaccine development, Philip Dormitzer, who joined the company after working at rival Pfizer, had told his GSK colleagues about the delay.

Pfizer Inc said on Monday annual revenue from its mRNA vaccine portfolio could reach $10 billion to $15 billion by 2030, alleviating fears of a sharp hit to its topline from an expected decline in ...

Feds probe disputed tip Pfizer held Covid vaccine results until after 2020 vote: WSJ President Trump has claimed in the past Pfizer sat on positive vaccine data, but no evidence has supported the ...

On May 16, Pfizer (PFE 0.38%) announced that it was going to take out $31 billion in fresh debt to pay for its purchase of Seagen , an oncology drug developer.

What Has Trump Said About Pfizer’s Covid Vaccine? Trump has alleged the Food and Drug Administration and Pfizer conspired with the so-called “medical deep state” to delay the release of ...

Pfizer on Wednesday revealed that it raised the list price of a course of Paxlovid—its lifesaving antiviral drug used to reduce the risk of severe COVID-19 in those most vulnerable—to nearly ...

Calculation context. Similar calculations were seen in Pfizer's trial: Of 17,411 vaccinated people, eight developed COVID-19 during the trial (0.045 percent), while 162 of 17,511 people in the ...

Pfizer said in a statement that the results will not impact its other planned collaborative studies of Paxlovid as a potential treatment for long COVID. Paxlovid is the most commonly prescribed at ...